Aytu Q1 FY2024: Adjusted EBITDA $2.2M (+32% YoY), ADHD revenue up 31%

AYTU BIOPHARMA, INC

2024-Q1 EPS reported -$1.48 revenue$22,099,000

Net revenue $22.1M (down 20% YoY) due to Consumer Health wind-down; Rx segment $17.8M.
ADHD net revenue $15.1M, up 31% YoY; pediatric revenue $2.6M impacted by payor changes.
Net loss $8.1M ($1.48/sh) vs $0.7M loss last year; includes $5.9M loss on derivative warrant liabilities.
Adjusted EBITDA $2.2M vs $1.7M YoY; Rx segment Adjusted EBITDA $2.4M.
Cash $20.0M at Sept 30, 2023; FDA approvals for manufacturing site transfers for Adzenys and Cotempla.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AYTU BIOPHARMA, INC reported fiscal quarter ended September 30, 2023 results: revenue $22.1 million, net income Net loss during Q1 2024 was $8.1 million, or $1.48 per share, EPS $1.48 per share.

Period: fiscal quarter ended September 30, 2023
Revenue: $22.1 million
Net income: Net loss during Q1 2024 was $8.1 million, or $1.48 per share
EPS: $1.48 per share
Result: reported results

Exact text from the filing

operational results for the first quarter of fiscal 2024 ended September 30, 2023. Q1 2024 Commercial Highlights (3 months ending September 30, 2023) · Total net revenue was $22.1 million, compared to $27.7 million. The change is primarily due to the planned wind down of the Company’s Consumer Health segment and the associated decrease in Consumer Health revenue.

View on SEC.gov

Browse all earnings releases →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-019023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.